Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -36.83% is 24% above its 5-year average of -48.16%, near the high end of its 5-year range (-213.48%–-26.33%).
As of the fiscal period ended Tuesday, June 30, 2026. 3.39% above its 12-month average of -38.12%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -36.83%.
RETURN ON INVESTED CAPITAL (ROIC)
-36.83%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-38.12%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-67.63%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
-48.16%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+3.39%
CURRENT VS 3Y AVG
+45.55%
CURRENT VS 5Y AVG
+23.53%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-35.64%
median of 838 covered companies
CURRENT VS SECTOR MEDIAN
-3.32%
vs the sector median at left
Candel Therapeutics, Inc.
Market Cap
$724.64M
Return on Invested Capital (ROIC)
-36.83%
TTM Avg
-38.12%
3Y Avg
-67.63%
5Y Avg
-48.16%
Market Cap
$721.40M
Return on Invested Capital (ROIC)
N/A
TTM Avg
-136.50%
3Y Avg
-154.74%
5Y Avg
-122.58%
Market Cap
$711.21M
Return on Invested Capital (ROIC)
-19.45%
TTM Avg
-59.05%
3Y Avg
-125.75%
5Y Avg
-106.53%
Market Cap
$745.49M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$710.66M
Return on Invested Capital (ROIC)
6.11%
TTM Avg
9.98%
3Y Avg
8.97%
5Y Avg
8.63%
Market Cap
$741.73M
Return on Invested Capital (ROIC)
-38.92%
TTM Avg
-31.45%
3Y Avg
-27.82%
5Y Avg
-24.27%
Market Cap
$700.60M
Return on Invested Capital (ROIC)
-12.00%
TTM Avg
-7.53%
3Y Avg
-5.45%
5Y Avg
-2.27%
Market Cap
$691.64M
Return on Invested Capital (ROIC)
-42.94%
TTM Avg
-42.70%
3Y Avg
-94.89%
5Y Avg
-93.87%
Market Cap
$755.18M
Return on Invested Capital (ROIC)
-42.83%
TTM Avg
-51.53%
3Y Avg
-51.53%
5Y Avg
-51.53%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $724.64M | -36.83% | -38.12% | -67.63% | -48.16% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $721.40M | N/A | -136.50% | -154.74% | -122.58% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $711.21M | -19.45% | -59.05% | -125.75% | -106.53% |
| Apnimed, Inc. (APMD)vs › | $745.49M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $710.66M | 6.11% | 9.98% | 8.97% | 8.63% |
| Design Therapeutics, Inc. (DSGN)vs › | $741.73M | -38.92% | -31.45% | -27.82% | -24.27% |
| Cytek Biosciences, Inc. (CTKB)vs › | $700.60M | -12.00% | -7.53% | -5.45% | -2.27% |
| Wave Life Sciences Ltd. (WVE)vs › | $691.64M | -42.94% | -42.70% | -94.89% | -93.87% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $755.18M | -42.83% | -51.53% | -51.53% | -51.53% |
| Faeth Therapeutics, Inc. (FTH)vs › | $688.55M | -110.62% | -99.41% | -74.42% | -73.36% |
ROIC
-36.8%
ROE
-70.2%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -36.83% |
| 2026-03-31 | -28.89% |
| 2025-12-31 | -41.38% |
| 2025-09-30 | -46.55% |
| 2025-06-30 | -36.96% |
| 2025-03-31 | -39.52% |
| 2024-12-31 | -42.12% |
| 2024-09-30 | -213.48% |
| 2024-06-30 | -156.12% |
| 2024-03-31 | -133.57% |
| 2023-12-31 | -103.97% |
| 2023-09-30 | -78.92% |
| 2023-06-30 | -66.78% |
| 2023-03-31 | -55.91% |
| 2022-12-31 | -47.32% |
| 2022-09-30 | -43.43% |
| 2022-06-30 | -38.33% |
| 2022-03-31 | -31.28% |
| 2021-12-31 | -30.68% |
| 2021-09-30 | -26.33% |
| 2021-06-30 | -71.74% |
| 2021-03-31 | -53.73% |
| 2020-12-31 | -40.58% |
